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Abstract
Background: Oral budesonide 9 mg/day represents first-line treatment of mild-to-moderately
active ileocolonic Crohn's disease. However, there is no precise recommendation for budesonide
dosing due to lack of comparative data. A once-daily (OD) 9 mg dose may improve adherence and
thereby efficacy.
Methods: An eight-week, double-blind, double-dummy randomised trial compared budesonide
9 mg OD versus 3 mg three-times daily (TID) in patients with mild-to-moderately active
ileocolonic Crohn's disease. Primary endpoint was clinical remission defined as CDAI b150 at
week 8 (last observation carried forward).
Results: The final intent-to-treat population comprised 471 patients (238 [9 mg OD], 233 [3 mg
TID]). The confirmatory population for the primary endpoint analysis was the interim per
protocol population (n = 377; 188 [9 mg OD], 189 [3 mg TID]), in which the primary endpoint was
statistically non-inferior with budesonide 9 mg OD versus 3 mg TID. Clinical remission was
achieved in 71.3% versus 75.1%, a difference of −3.9% (95% CI [−14.6%; 6.4%]; p = 0.020 for
non-inferiority). The mean (SD) time to remission was 21.9 (13.8) days versus 21.4 (14.6) days
with budesonide 9 mg OD versus 3 mg TID, respectively. In a subpopulation of 122 patients with
baseline SES-CD ulcer score≥1, complete mucosal healing occurred in 32.8% (21/64) on 9 mg OD
and 41.4% (24/58) on 3 mg TID; deep remission (mucosal healing and clinical remission) was
observed in 26.6% (17/64) and 32.8% (19/58) of patients, respectively. Treatment-emergent
suspected adverse drug reactions were reported in 4.6% of 9 mg OD and 4.7% of 3 mg TID
patients.
Conclusions: Budesonide at the recommended dose of 9 mg/day can be administered OD
without impaired efficacy and safety compared to 3 mg TID dosing in mild-to-moderately active
Crohn's disease.
© 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V.license.Open access under CC BY-NC-ND 1. Introduction
Systemic glucocorticosteroids are highly effective for inducing
remission in patients with active Crohn's disease, but are
associated with a high rate of potentially serious side effects.1
‘Second generation’ topical glucocorticosteroids such as
budesonide have been developed which preserve efficacy but
have lower systemic toxicity and a more favourable safety
profile.2,3 Randomised clinical studies have shown that
budesonide therapy leads to remission in 50–60% of patients
with active ileocolonic Crohn's Disease.4–8 The EuropeanCrohn's
and Colitis Organisation (ECCO) recommends oral treatment
with budesonide at a dose of 9 mg/day as first-line treatment of
mild-to-moderately active, ileocolonic Crohn's Disease.9 How-
ever, there is no clear recommendation for a precise regimen
of budesonide intake, 9 mg/day once daily (OD) or 3 mg three
times a day (TID), due to lack of comparative data. It is
estimated that 30–45% of patients with inflammatory bowel
disease are non-adherent to oral medication schedules10 and
although the causes of non-adherence to medication in inflam-
matory bowel disease are complex,10–12 multiple daily dosing is
known to discourage adherence.13
In a recent double-blind, double-dummy trial, oral budes-
onide administered either as 9 mg OD or as 3 mg TID was at
least as effective as high-dose oral mesalazine (4.5 g/day) in
moderately active Crohn's disease.8 In an exploratory analysis,
the primary endpoint of clinical remission was found to be
similar with OD or TID budesonide dosing. The objective of the
current eight-week, double-blind, double-dummy randomisedtrial was to compare the efficacy and tolerability of budesonide
9 mg OD versus 3 mg TID in patients with mild-to-moderately
active ileocolonic Crohn's disease in a confirmatory manner. In
addition to the primary efficacy endpoint of clinical remission,
achievement of mucosal healing in each treatment group was
also examined.2. Methods
2.1. Study design and conduct
This was a double-blind, double-dummy, randomised,
multicentre, Phase III study in which patients with mild-to-
moderately active ileocolonic Crohn's disease received
budesonide at a single daily dose of 9 mg or three daily doses
of 3 mg. After screening, an eight-week treatment phase was
followed by a two-week follow-up period. The study was
planned as a three-stage adaptive design with possible sample
size adjustment after pre-specified interim analyses. The first
patient visit was in November 2009 with the last visit of the
treatment phase in April 2012.
The study was undertaken at 50 gastroenterology centres in
Bulgaria, Czech Republic, Germany, Hungary, Latvia, Lithuania,
Romania, Russia, Slovakia, and Ukraine. It was conducted in
compliance with Good Clinical Practice and the Declaration of
Helsinki following approval from the relevant independent
ethics committee at each centre.Written informed consentwas
obtained from all participants.
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Adult patients (18–75 years) with mild-to-moderately active
Crohn's disease (defined as Crohn's Disease Activity Index [CDAI]
scores N200 and b400) localised in the terminal ileum, coecum,
ascending colon or ileocolitis were eligible, if (i) they had
experienced symptoms of Crohn's disease for at least three
months, (ii) diagnosis had been confirmed by endoscopy and
histology, or by endoscopy and radiology. If endoscopy had been
performed ≥12 months previously, then clinical signs and
behaviour according to the Montreal classification14 were to
be unchanged compared to former episodes. Key exclusion
criteria were known Crohn's lesions in the upper gastrointestinal
tract (defined as up to and including the jejunum) or rectum
with current symptoms; septic complications; evidence of
infectious diarrhoea (i.e. pathogenic bacteria in stool culture);
the presence of abscesses, perforation, or active fistulas;
ileostomy or colostomy; resection of more than 50 cm of the
ileum; bowel surgery within the last three months; indication
for immediate surgery; clinical signs of stricturing disease;
subileus within the last six months or suspicion of ileus, subileus
or corresponding symptoms, abnormal hepatic or renal func-
tion; any severe concomitant cardiovascular, renal, endocrine,
or psychiatric disorder; a history of metastatic cancer in the last
five years; treatment with immunosuppressants or anti-cancer
drugs, e.g. thiopurines, methotrexate, tacrolimus, cyclophos-
phamide or cyclosporine within the last three months (treat-
mentwith thiopurines was permitted if used formaintenance of
remission only at an unchanged dose within the three months
prior to the baseline visit and during the study); treatment with
ketoconazole or other CYP3A inhibitors, or with anti-TNF-α
therapy, within three months prior to the baseline visit;
treatment with conventional or inhaled steroids, or with oral
budesonide N6 mg/day, within two weeks prior to the baseline
visit; steroid-refractory disease; treatment of Crohn's disease
with oral antibiotics or non-steroidal anti-inflammatory drugs
within two weeks prior to the baseline visit (≤350 mg/day or
short-term acetylsalicylic acid was permitted).2.3. Randomisation and intervention
Patients who met the enrolment criteria at the baseline visit
were included into the double-blind treatment phase
and were given a 4-digit randomisation number derived
from a computer-generated list that used randomly permut-
ed blocks (RANCODE software, IDV Gauting, Germany). The
central randomisation list was held by staff at the contract
research organisation who were not involved in the study
conduct. Randomisation numbers were assigned consecu-
tively in each centre in the order of patients' inclusion into
the double-blind treatment phase, i.e. randomisation was
stratified by centre. Patients received the study medication
marked with their randomisation number. The first dose of
study drug was to be taken on the day after randomisation.
Patients were randomised in a 1:1 ratio to receive a 9 mg
sachet of budesonide granules (Budenofalk® Uno 9 mg
granules, Dr Falk Pharma GmbH, Freiburg, Germany) OD in
the morning with one placebo capsule TID, or one sachet of
placebo granules OD in the morning and 3 mg capsules of
budesonide (Budenofalk® 3 mg capsules, Dr Falk Pharma
GmbH, Freiburg, Germany) TID. The appearance and size ofthe sachets and capsules of budesonide or placebo were
identical to preserve the double-dummy nature of the trial.
2.4. Evaluation
Study visits took place at baseline and at weeks 2, 4, 6 and 8,
with a follow-up visit two weeks after the end of the study.
Study drug intake was determined by counting returned unused
medication. Each patient also recorded study drug intake in a
daily diary. CDAI score was recorded at each visit during the
treatment phase.15,16 Data for three of these variables were
derived from patient diaries from the preceding seven days. If
fewer than five days of documentationwere available, CDAIwas
regarded as invalid. Endoscopy and determination of the Simple
Endoscopic Score for Crohn's Disease (SES-CD)17 were optionally
assessed at baseline and week 8. The total SES-CD score was
calculated as the sum of five bowel segment scores (rectum,
left colon, transverse colon, right colon and ileum), ranging
from 0 to 56, with higher scores indicating more severe disease.
The Short Health Scale (SHS) was administered at each study
visit. SHS is a simplified four-item questionnaire based on
four questions relating to symptom burden, social function,
disease-related worry and general well-being, scored by the
patient on visual analogue scales.18,19 Higher SHS values
indicate higher burden. The Gastrointestinal Quality of Life
Index (GIQLI) was assessed at baseline, week 4 and week 8. The
global GIQLI score ranges from 0 to 144.20,21 Higher GIQLI values
indicate better quality of life. Physician's Global Assessment
(PGA)22 was undertaken at the end of treatment or last
study visit. Using the six-point PGA scale, physicians classified
the change in the patient's condition as complete relief of
symptoms, marked improvement of symptoms, moderate
improvement of symptoms, slight improvement of symptoms,
no change in symptoms or worsening of symptoms. Central
laboratory evaluations were performed at all study visits,
including haematology, serum chemistry, kidney and liver
function tests, and C-reactive protein (CRP). Morning serum
cortisol was measured by the central laboratory on a Roche
Modular E170 Analyzer using an electrochemiluminescence
immunoassay (Elecsys Cortisol, Roche Diagnostics, Mannheim,
Germany) at baseline and at week 8/withdrawal visit. At these
visits, blood samples were to be drawn between 8 a.m. and
9 a.m., and at the same time for a particular patient whenever
possible. Adverse events (AEs) were monitored at each study
visit. Tolerability was classified as ‘very good’, ‘good’,
‘satisfactory’ or ‘poor’ by investigator and patient indepen-
dently at week 8 or the last study visit.
2.5. Study endpoints
The primary endpoint was the rate of clinical remission,
defined as CDAI b150 at week 8 using the last observation
carried forward (LOCF) method. In the event of discontin-
uation due to lack of efficacy or if no follow-up CDAI was
documented after baseline, ‘non-remission’ was assumed.
Secondary efficacy variables included the rate of clinical
remission at weeks 2, 4, 6 and 8; the time to clinical
remission; the change in CDAI score from baseline to weeks
2, 4, 6 and 8 (LOCF); complete mucosal healing at week 8
(LOCF), defined as an SES-CD score of 0 on the subscore for
size of ulcer in all bowel segments (SES-CDulcer)23, change in
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GIQLI score from baseline to week 8 (LOCF); and therapeutic
success (defined as complete relief of symptoms or marked
improvement of symptoms on the PGA scale from baseline to
week 8 [LOCF]) or therapeutic benefit (defined as any
improvement on the PGA scale from baseline to week 8
[LOCF]). As a post-hoc analysis the rate of deep remission at
week 8 (LOCF) was assessed, defined as complete mucosal
healing with clinical remission. Safety variables included
AEs, vital signs, laboratory parameters (including morning
serum cortisol), and assessment of tolerability by the inves-
tigator and the patient (‘very good’, ‘good’, ‘satisfactory’ or
‘poor’). AEs were reported if they first occurred, or were
pre-existing but worsened, after the start of study drug
treatment and during the treatment period (‘treatment-
emergent’ AEs).2.6. Statistical analysis
The study used a group-sequential adaptive design, whereby
pre-planned interim analyses were successively undertaken
after observation of 201, 301 and 401 intention-to-treat
(ITT) patients. Following the third interim analysis, the
Independent Data Monitoring Committee recommended that
no further patients be recruited since non-inferiority of
budesonide 9 mg OD versus 3 mg TID was shown to be
confirmed. Patients already recruited at the time of the
decision continued in the study, such that the final study
population included 471 patients. All patients and staff
involved in the conduct and final analysis of the study,
including the sponsor, remained blinded to the results of
the interim analyses. Access to unblinded data was restrict-
ed to the members of the Independent Data Monitoring
Committee and to the unblinded statistician of the contract
research organisation who was external to the sponsor and
was not involved in the study conduct or the final analysis.
Confirmatory analysis of the primary endpoint was based
on the interim population, with a sensitivity analysis based
on the final study population. The primary analysis for
confirmatory testing was based on the per protocol (PP)
population, as the more conservative approach, with an
exploratory analysis in the ITT population. A non-inferiority
test with a one-sided significance level of α = 0.025 and
a non-inferiority margin of −15% was used, based on the
inverse normal method of combining the p-values of the
shifted asymptotic χ2 test for comparing two rates and
maximum likelihood estimation for the unknown parame-
ters.24 The confidence interval (CI) limit of 15% was selected
based on an expected remission rate of 55% in both the
budesonide 9 mg OD group and the 3 mg TID group, well
above the reported placebo remission rate of 25% 25,26
assuring a clinically relevant effect superior to a putative
placebo and no clinically relevant inferiority to the control
group. A two-sample t-test was used to compare CDAI
change from baseline to week 8 (LOCF). Changes from
baseline in total SES-CD score, and in SHS and GIQLI scores,
were compared between treatment groups using the two-
sided Wilcoxon test for independent samples. Mucosal
healing, deep remission, therapeutic success, and therapeu-
tic benefit were compared between treatment groups using
Chi-Square tests. Fisher's exact test was used when theexpected cell counts were less than five. Changes from
baseline in cortisol or electrolytes were compared between
treatment groups using the Wilcoxon two-sample test. Base-
line and week 8 (LOCF) values of these parameters were
compared within each treatment group using the Wilcoxon
Signed Rank test and were based on the subsets of patients
with both a baseline and a week 8 (LOCF) value. Tests for
secondary endpoints always tested the null hypothesis of
equality of treatment groups (or of baseline and week 8
[LOCF] cortisol, sodium and potassium, respectively); small
p-values indicate differences.
The ITT population included all randomised patients
who received at least one dose of study medication. The
PP population included all ITT patients without pre-specified
major violations of eligibility criteria or other major protocol
deviations. The decision to exclude a patient from the PP
population was made during a blinded data review prior
to breaking the code. The safety analysis set included all
ITT patients who provided at least one follow-up safety
evaluation.
3. Results
3.1. Study population and treatment
In total, 473 patients were randomised. Two patients did
not receive study medication such that the final ITT study
population comprised 471 patients (238 [9 mg OD], 233
[3 mg TID]) (Fig. 1). Of these, 401 formed the interim
analysis ITT population (200 [9 mg OD], 201 [3 mg TID]). The
study was discontinued prematurely by 23 patients in the ITT
population, most frequently due to lack of patient cooper-
ation (Fig. 1). The PP final study population included 439
patients (220 [9 mg OD], 219 [3 mg TID]) and the confirma-
tory interim PP population included 377 patients (188 [9 mg
OD], 189 [3 mg TID]). Premature withdrawal unrelated to
study medication was the most frequent reason for exclusion
from the PP population (Fig. 1).
The demographic characteristics of the two treatment
groups were similar (Table 1). Other than slightly higher
mean total CDAI and SES-CD scores in the budesonide 9 mg
OD group, no clinically relevant differences between treat-
ment groups were observed. The median time since the first
onset of symptoms was 3.0 years in the budesonide 9 mg OD
and 4.0 years in the 3 mg TID groups.
The mean (SD) treatment duration in the study was
54.1 days (7.1) in the budesonide 9 mg OD group and
54.4 days (8.0) in the 3 mg TID group. The mean (SD)
adherence rate with regard to intake of budesonide was
99.9% (7.6%) in the budesonide 9 mg OD group and 98.9%
(8.2%) in the 3 mg TID group. All but ten patients (3 [9 mg
OD], 7 [3 mg TID]) were adherent to treatment (≥75%).
Concomitant medication in the category ‘alimentary tract
and metabolism’ was used by 87.4% of patients (208/238)
in the budesonide 9 mg OD group and 84.5% (197/233) of the
3 mg TID group.
3.2. Clinical remission and symptom severity
The primary endpoint, the rate of clinical remission (CDAI
b150 at week 8 [LOCF]), was statistically non-inferior in the
Figure 1 Patient disposition (final study ITT population). ITT, intention-to-treat; PP, per protocol.
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PP population (the primary analysis set) as well as in the
ITT interim population (Fig. 2). The proportion of patients
with clinical remission was 71.3% versus 75.1%, respectively,
a difference of −3.9% (95% CI [−14.6%; 6.4%], p = 0.020 for
non-inferiority based on the pre-specified margin of −15%).
The ITT analysis led to similar but slightly lower remission
rates in both groups (68.5% versus 71.1%), but non-inferiority
was again shown (Fig. 2). Results from a sensitivity analysis
based on the full study population showed similar results in
the PP population but the lower limit of the 95% CI for the
difference between groups in the final study ITT population
was 15.1% i.e. non-inferiority was borderline (Fig. 2).
The rate of clinical remission was similar in both treatment
groups at all time points during the eight-week study (Fig. 3a),Table 1 Patient demographics and baseline characteristics (fina
Male gender, n (%)
Age (years), mean (SD)
Smoker, n (%)
Time since first symptoms (years), median (range)
Localisation of disease, n (%)
Ileum and/or ascending colon only
Only ileum and/or ascending and distal colon
Concomitant treatment, n (%)
Mesalazine
Azathioprine
Baseline CRP (mg/L), mean (SD)
Baseline SES-CD, mean (SD)
Baseline CDAI, mean (SD)
CDAI, Crohn's Disease Activity Index; CRP, C-reactive protein; ITT, inte
Score for Crohn's Disease.
a n = 100.
b n = 93.as was the mean (SD) time to remission (budesonide 9 mg OD
21.9 [13.8] days, budesonide 3 mg TID 21.4 [14.6] days).
The improvement in the mean CDAI score followed a
similar course in both groups (Fig. 3b). At week 8 (LOCF),
the mean (SD) change from baseline in CDAI was nearly
identical: −153.3 points (83.4) in the budesonide 9 mg OD
and −153.2 points (81.6) in the 3 mg TID groups, respec-
tively. The difference [95% CI] between these changes from
baseline was −0.1 [−15.2; 14.9] with p = 0.989, highlighting
the therapeutic equivalence of the two dosing regimens.
3.3. Mucosal healing
Endoscopy, an optional assessment, was performed both at
baseline and week 8 for 72 patients (30.3%) in the 9 mg ODl study ITT population).
Budesonide 9 mg OD
(n = 238)
Budesonide 3 mg TID
(n = 233)
109 (45.8) 104 (44.6)
38.2 (13.5) 40.6 (13.5)
34 (14.3) 39 (16.7)
3.0 (0–43) 4.0 (0–42)
154 (64.7) 159 (68.2)
84 (35.3) 74 (31.8)
167 (70.2) 148 (63.5)
27 (11.3) 23 (9.9)
10.0 (19.0) 8.6 (15.6)
8.5 (5.3) a 7.9 (5.2) b
271 (50.1) 264 (42.8)
ntion-to-treat; SD, standard deviation; SES-CD, Simple Endoscopic
Figure 2 Clinical remission at week 8 (LOCF). Results are shown
for the interim population (confirmative analysis) and the full
study population (explorative analysis).
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mean (SD) SES-CD total score at baseline was 8.5 (5.3) in the
budesonide 9 mg OD group versus 7.9 (5.2) with 3 mg TID,Figure 3 (a) Rate of clinical remission and (b) mean [SD] CDAI
score during the study according to treatment group (final study
ITT population). CDAI, Crohn's Disease Activity Index.compared to 4.0 (4.2) versus 3.6 (4.5) at week 8 (LOCF). The
mean (SD) change from baseline to week 8 (LOCF) in the
total SES-CD score was numerically greater in the 9 mg OD
group (−4.3 [4.2]) compared to the 3 mg TID group (−3.4
[3.5]), but did not reach statistical significance (p = 0.372).
However, when the change in SES-CD score was compared
between treatment groups by bowel segment, the mean (SD)
improvement from baseline was significantly greater in the
budesonide 9 mg OD group (−1.8 [1.8]; n = 67) versus the
3 mg TID group (−1.1 [1.7], n = 56) for the ileum (difference
[95% CI] of −0.7 [−1.3; −0.1], p = 0.017) but not in other
segments. When SES-CD subscore data (i.e., size of ulcer,
ulcerated surface, affected surface, presence of stenosis)
were compared, there was a greater mean (SD) decrease in
the size of the affected area with 9 mg OD dosing versus
3 mg TID dosing (−1.5 [1.5], n = 72 versus −0.9 [1.1], n = 63;
difference [95% CI] of −0.6 [−1.0; −0.1], p = 0.037) but other
subscores showed no significant difference.
Complete mucosal healing, defined as SES-CDulcer score
of 0 in all bowel segments as well as in a post-hoc analysis
‘deep remission’ (defined as mucosal healing and clinical
remission at week 8 [LOCF]) was achieved in a substantial
proportion of patients in both treatment groups (Table 2).
No statistically significant differences between the groups
were observed. The mucosal healing rate in the two most
frequent areas of mucosal damage, i.e., the right colon and
the ileum, was 52.8% (19/36) and 46.9% (23/49), respec-
tively in the 9 mg OD group and 60.5% (26/43) and 39.4%
(13/33), respectively in the 3 mg TID group, respectively,
indicating a comparable efficacy for both dosing regimens
for the induction of mucosal healing in the most frequent
location of ‘ileal disease’.
3.4. Quality of life
Both treatment arms demonstrated an improvement in quality
of life indices from baseline to week 8 (Table 2). The change
in SHS dimensions and the GIQLI global score during the
eight-week treatment period was comparable between treat-
ment groups (Table 2). No statistically significant differences
between the groups were observed.
3.5. Therapeutic effect
Therapeutic success (defined as complete relief of symp-
toms or marked improvement of symptoms on the PGA scale
from baseline to week 8) was achieved in approximately 68%
of patients in each treatment group (Table 2). Therapeutic
benefit (defined as any improvement on the PGA scale from
baseline to week 8) occurred in more than 90% of patients in
each group. No statistically significant differences between
the groups were observed.
3.6. Safety and tolerability
The frequency of treatment-emergent AEs (i.e. whether or
not considered related to the intake of the study drug during
the double-blind treatment period), was similar in the
budesonide 9 mg OD and the 3 mg TID groups (26.6% and
21.1% of patients, respectively). Headache and gastroin-
testinal disorders were the most frequently reported AEs
Table 2 Secondary efficacy endpoints at week 8 (LOCF) (final study ITT population).
Budesonide 9 mg OD Budesonide 3 mg TID p value
n Value n Value
Patients with baseline and wk 8 (LOCF) endoscopy experiencing:
Complete mucosal healing at wk 8 (LOCF), n (%) a 72 b 30 (41.7) 63 c 30 (47.6) 0.488 d
Deep remission at wk 8 (LOCF), n (%) e 72 b 26 (36.1) 63 c 24 (38.1) 0.812 d
Change in SES-CD total score from baseline to wk 8 (LOCF), mean (SD) 72 −4.3 (4.2) 63 −3.4 (3.5) 0.372 f
Patients with baseline SES-CD ulcer score of ≥1 experiencing:
Complete mucosal healing at wk 8 (LOCF), n (%) a 64 21 (32.8) 58 24 (41.4) 0.327 d
Deep remission at wk 8 (LOCF), n (%) e 64 b 17 (26.6) 58 c 19 (32.8) 0.454 d
Change in SES-CD total score from baseline to wk 8 (LOCF), mean (SD) 64 c −4.8 (4.2) 58 c −3.7 (3.5) 0.220 f
Change [mm] in SHS 100 mm VAS dimensions from baseline to week 8 (LOCF),
mean (SD) g
236 230
Severity of symptoms −25.3 (25.7) −24.7 (25.4) 0.555 f
Interference with daily life −25.8 (26.8) −26.4 (27.2) 0.967 f
Worry −25.4 (26.7) −27.6 (26.6) 0.472 f
Well-being −23.3 (23.9) −24.2 (23.8) 0.837 f
Change in GIQLI global score [range 0–4] from baseline to week 8 (LOCF),
mean (SD) h
230 0.61 (0.56) 227 0.58 (0.49) 0.483 f
Therapeutic success, n (%) i 238 b 161 (67.6) 233 c 160 (68.7) 0.812 d
Therapeutic benefit, n (%) j 238 b 222 (93.3) 233 c 213 (91.4) 0.447 d
GIQLI, Gastrointestinal Quality of Life Index; LOCF, last observation carried forward; SD, standard deviation; SES-CD, Simple Endoscopic
Score for Crohn's Disease; VAS, Visual Analogue Scale.
a SES-CDulcer score 0 in all bowel segments.
b The variable was missing or not evaluable in two of these patients.
c The variable was missing or not evaluable in one of these patients.
d Chi-Square test (not evaluable or missing counted as ‘no’).
e Complete mucosal healing and clinical remission (CDAI b150) at week 8 (LOCF).
f Two-sided Wilcoxon-test for independent samples.
g Short Health Score. Higher values indicate greater burden.
h Gastrointestinal Quality of Life Index. Higher values indicate better quality of life.
i Complete relief of symptoms or marked improvement of symptoms on the PGA scale from baseline to week 8 (LOCF).
j Any improvement on the PGA scale from baseline to week 8 (LOCF).
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reactions (i.e., causal relationship between the study drug
and the AE is at least a reasonable possibility) were much
less common (4.6% [9 mg OD] and 4.7% [3 mg TID]). None of
the five serious AEs was classified by the investigators as a
suspected adverse drug reaction. In total, eight patients
discontinued the study due to AEs: 3 patients (1.3%) in the
budesonide 9 mg OD group and five patients (2.2%) in the
3 mg TID group.Table 3 Number (%) of patients experiencing treatment-emerge
treatment group, n (%) (safety population).
Budesonide 9
Any treatment-emergent adverse event 63 (26.6)
Headache 18 (7.6)
Abdominal pain 7 (3.0)
Upper abdominal pain 4 (1.7)
Dyspepsia 3 (1.3)
Viral respiratory tract infection 4 (1.7)
Crohn's disease a 3 (1.3)
Nasopharyngitis 1 (0.4)
Constipation 3 (1.3)
Oropharyngeal pain 3 (1.3)
a Deterioration during the study.Clinical laboratory evaluations did not raise a safety con-
cern. Fig. 4 shows morning serum cortisol levels (between
8 a.m. and 9 a.m.) at baseline and after eight weeks of
continuous treatment. The decrease in endogenous cortisol
secretion was statistically significant in each treatment
group (p b 0.001). Interestingly, the decrease in morning
serum cortisol levels after eight weeks of treatment was less
pronounced following OD dosing (statistically not significant
between the groups). A comparison of serum sodium andnt adverse events occurring in at least 1% of patients in either
mg OD (n = 237) Budesonide 3 mg TID (n = 232)
49 (21.1)
12 (5.2)
2 (0.9)
4 (1.7)
4 (1.7)
2 (0.9)
2 (0.9)
3 (1.3)
–
–
Figure 4 Mean (SD) serum cortisol levels (8 a.m. to 9 a.m.)
during the study according to treatment group (safety popula-
tion). Dashed line presents the lower limit of normal.
977Budesonide once versus three times daily for CDserum potassium levels at baseline with those after eight
weeks of treatment did not show a clinically relevant effect
on electrolyte balance in either treatment group (Fig. 5).
Tolerability was assessed as “very good” or “good” by
94.9% and 94.4% of patients (and by 95.8% and 96.6% of
investigators) in the budesonide 9 mg OD group and the 3 mg
TID group, respectively.Figure 5 (a) Mean (SD) serum sodium levels and (b) mean (SD)
serum potassium levels during the study according to treatment
group (safety population). Dashed lines represent the limits
of normal. White bars: baseline; black bars: week 8 (LOCF);
*p = 0.041, **p = 0.004 (baseline vs. week 8 [LOCF]). Statistical
comparison between groups: n.s.4. Discussion
The results of this double-blind, double-dummy, multicentre
trial show that OD administration of budesonide 9 mg offers
similar efficacy to 3 mg three-times daily dosing in terms
of achieving clinical remission in mild-to-moderately active
ileocolonic Crohn's disease. Clinical remission was achieved
by approximately 70% of patients in both groups during the
eight-week study and, notably, complete mucosal healing
occurred in over 30% of patients. There were no clinically
relevant differences between the two regimens in the rate at
which remission was achieved, in the extent of mucosal healing
or in the improvement of patients' quality of life. The safety
profiles and tolerability of OD or TID dosing were also similar.
These findings suggest that once-daily budesonide should be
used in preference to multiple daily dosing in this setting to
support adherence to treatment in patients with active Crohn's
disease.
The primary efficacy variablewas clinical remission based on
the CDAI, as recommended in the recent European Medicines
Agency guidelines.27 Baseline CDAI values were similar to those
reported in other studies with budesonide in Crohn's dis-
ease.5,7,8,28,29 Non-inferiority of budesonide 9 mg OD compared
to budesonide 3 mg TIDwas confirmed in the PP population (the
primary analysis population) as well as in the ITT population of
the interim analysis. In the full study population, a sensitivity
analysis again showed non-inferiority for the OD regimen in the
PP population but did not quite reach significance in the ITT
population based on pre-specified statistical criteria. The mean
reduction in CDAI during the treatment period was identical
with either OD or TID dosing, and was similar to that reported
in previous trials of budesonide8 and mesalazine30 in mild-to-
moderately active Crohn's disease. Other efficacy endpoints
were virtually the same in both groups.
When comparing the obtained remission rates with the ones
from other studies in Crohn's disease with oral budesonide
formulations, one has to keep in mind that the available
pharmaceutical formulations, i.e., Entocort® and Budenofalk®,
differ in their release-profiles, which might have an influence
on the obtained remission rates. The remission rates in the
current study were very similar to the ones recently reported
with Budenofalk® capsules in a large phase III study by Tromm
et al. (67–72%).8 Earlier studies with Budenofalk® capsules
reported slightly lower remission rates in the range of 51–
56%.5–7 Reasons remain speculative, as the baseline character-
istics, inclusion criteria, and daily dose of budesonide did not
reveal conspicuous differences. For example, the baseline
mean CDAI in all trials with Budenofalk® capsules, including
the current one, was very comparable (range: 260–271 points),
and thus could be excluded as a potential reason for these
differences. The lowest remission rate (51%) was observed
in the study by Bar-Meir et al.5 which enrolled however, more
smokers (approximately 30%) compared to only 15% in the
current study. As smoking is a negative predictor for the
outcome in Crohn's disease, this might be one potential
explanation for the lower remission rate observed in the
Bar-Meir study.
Mucosal healing is associated with a reduced risk of
relapse, hospitalisation, fistulas and surgery,31 and is
increasingly recognised as a valuable endpoint for assessing
the efficacy of interventions for Crohn's disease.32 To date,
no randomised controlled study of oral budesonide in
978 A. Dignass et al.mild-to-moderately active Crohn's disease has included
endoscopic endpoints. In our population, endoscopic data
were available at baseline and at the end of treatment for
more than a quarter of patients in each group. Encouraging-
ly, complete mucosal healing was observed in approximately
33% and 41% of patients, respectively, in the budesonide
9 mg OD or 3 mg TID groups. Moreover, approximately 30%
of patients achieved both mucosal healing and clinical
remission after only eight weeks of treatment. For compar-
ison, the recent EXTEND study reported mucosal healing
in 27% of patients and deep remission in 16% of patients
after 12 weeks' treatment with adalimumab; however, that
population had more severe disease at baseline.33
In the ileum and right colon, where the release of oral
budesonide starts using the Budenofalk® formulation, the
average rate of mucosal healing was approximately 50%
in both groups in our population. There was a numerically
greater improvement in SES-CD score in the budesonide
9 mg OD group versus TID dosing, which reached significance
in the ileum, suggesting that once-daily dosing may be
beneficial with regard to mucosal healing in ileocolonic
Crohn's disease.
Safety analysis did not reveal any clinically relevant
difference between the two different dosage regimens. The
presented clinical trial confirmed the well-known safety
profile of oral budesonide with a low rate of side effects in
active Crohn's disease. The trend to lower morning serum
cortisol in the 3 mg TID arm as compared to 9 mg OD dosing
was already noted in another clinical trial using budesonide
in mildly-to-moderately active Crohn's disease,8 and might
be an argument for preference of OD dosing in patients with
pre-existing adrenal suppression.
Adherence to the prescribed regimen was high in both
treatment arms, based on returned medication and patient
diaries, despite the requirement to take one sachet and three
capsules per day. The close monitoring of a controlled trial
of this type, and the short eight-week duration of therapy, are
likely to have contributed to this level of adherence. It needs
to be emphasized that a clinical trial setting is likely to produce
much higher adherence rates than a real-life setting, where
significantly lower rates have been reported. A systematic
review of adherence studies in inflammatory bowel disease
concluded that over a third of patients are non-adherent,10 and
that more complex regimens such as TID dosing tend to predict
non-adherence10 as described for other chronic diseases.34,35
In conclusion, budesonide at the recommended dose of
9 mg/day can be administered once a day without any loss
of efficacy compared to conventional TID dosing in mild-to-
moderately active Crohn's disease, with potential benefits for
long-term adherence. The high rates of clinical remission and
mucosal healing achieved in both treatment arms following
an eight-week treatment period support recent recommenda-
tions that oral budesonide should be used first-line to in-
duce remission in mild-to-moderately active ileocecal Crohn's
disease.9,36,37Role of funding source
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Appendix A. Study investigators
Bulgaria: S. Stoynov, P. Penchev, H. Kadian (Sofia); I. Kotzev, M.
Stamboliyska, A. Atanassova (Varna); A. Petrov, A. Chavushian,
R. Balabanska, R. Tsonev (Sofia); G. Vasileva, Y. Novakov
(Rousse); D. Kurktschiev, T. Temelkova-Kurktschiev (Sofia).
Czech Republic: M. Lukas, M. Bortlik (Prague); L. Gabalec, V.
Šimon (Ústí nadOrlicí); A. Jungwirthová, P.Matějková (Prague);
M. Široký, L. Slezák (Hradec Králové); E. Tomsová, J. Marček
(Mladá Boleslav); P. Benko, J. Goláňová, V. Komárek (Prague).
Germany: A. Dignass, M. Böhmig, H.A. Schulze (Frankfurt
am Main); H.J. Cordes, A. Dienethal, R. Claudé (Frankfurt
am Main); T. Klugmann, N. Teich, A. Borkenhagen (Leipzig);
M. Schroeder, H Hinrichsen (Kiel).
Hungary: Z. Tulassay, L. Herszényi, M. Juhász, P. Miheller, E.
Mihály (Budapest); I. Altorjay, K. Palatka, S. Kacska (Debrecen);
P. Demeter, J. Penyige, R. Sike (Budapest); G. Mester, M.
Balogh (Pápa); I. Rácz, A. Szabó, T. Karasz, M. Csöndes (Györ).
Latvia: J. Pokrotnieks, A. Pukitis (Riga); J. Derova, A.
Derovs (Riga).
979Budesonide once versus three times daily for CDLithuania: L. Kupčinskas, L. Jonaitis, G. Kiudelis (Kaunas);
A. Buinevičiūtė, G. Radžiūnas (Vilnius).
Romania: V. Cristea, C.C. Burz, D. Muti (Cluj-Napoca); I.
Dina, C. Iacobescu (Bucharest); O. Fratila, T. Ilias (Oradea);
L. Gheorghe, G. Smira, R. Vadan (Bucharest); A. Goldis, F.
Bob, R. Goldis, S. Kallikkot (Timisoara); D. Tuculanu, M.G.
Paunescu, S. Covasintan (Timisoara).
Russia: E.A. Belousova, I.V. Domareva (Moscow); G.A.
Grigorieva*, N.Y. Meshalkina, S.V. Golysheva (Moscow); V.B.
Grinevich, I.V. Gubonina, A.M. Pershko (St. Petersburg); T.L.
Mikhailova**, O.V. Golovenko, L.A. Mayat, P.A. Makarchuk
(Moscow); V.I. Simanenkov, N.V. Zakharova, G.N. Belov (St.
Petersburg); E.A. Sishkova, T.V. Tinyakova, D.V. Raspereza (St.
Petersburg); E.I. Tkachenko, E.B. Avalueva, T.N. Zhigalova, E.
Skazyvaeva, E. Mirgorodskaya (St. Petersburg); E.P. Yakovenko,
N.A. Agafonova, A.N. Ivanov, A.V. Yakovenko, A.S.
Pryanishnikova (Moscow); D.I. Abdulganiyeva, A.H. Odintsova,
E.S. Bodryagina, S.G. Glebasheva (Kazan); O.P. Alekseeva, S.V.
Krishtopenko (Nizhniy Novgorod); O.Y. Dolgikh, P.P. Andreev,
A.V. Lukashova (Samara); V.V. Pavlenko, S.B. Aleksandrovna,
G.A. Kataganova, N.V. Korablina (Stavropol); B.D. Starostin, G.
Starostina (St. Petersburg); A.V. Tkachev, K.E. Nikitina, L.S.
Mkrtchyan (Rostov-on-Don); A.A. Yakovlev, I.G. Stolyarova, A.S.
Volkov, V. Krishchenko (Rostov-on-Don); E.Y. Valuiskikh, O.M.
Gilinskaya, E. Miroshnichenko (Novosibirsk).
Slovakia: B. Barický (Nitra); I. Bunganič (Prešov); B.
Pekárková, B. Pekárek (Trnava).
Ukraine: O.I. Golovchenko, I.A. Nosova, O.N. Zaporozhets
(Vinnnitsya); A.E. Dorofeyev, O.A. Rassokhina (Donetsk);
Y.S. Lozynskyy, O.V. Leoshyk, I.V. Seplyvyy (Lviv); M.P.
Zakharash, Y.M. Zakharash, T.G. Kravchenko (Kyiv).
*Prof. Dr. G.A. Grigorieva (Moscow) recently passed
away.
**Prof. Dr. T.L. Mikhailova (Moscow) recently passed
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